# US 2025/0145674 A1 · Novel Protein, and Therapeutic and Cosmetic Uses Thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0145674 A1
- Document ID: US20250145674A1
- Status: Published application
- Kind: A1
- Application number: 19/014,438
- Filed: 2025-01-09
- Published: 2025-05-08
- Earliest claimed: 2020-05-06
- Assignees: Quorum Innovations, LLC
- Applicants: Quorum Innovations, LLC
- Inventors: Nicholas T. MONSUL; Eva A. BERKES; Frederick T. BOEHM; Yu-Hsien LIAO
- Web page: https://patentgrep.com/patent/US20250145674A1

## CPC

- C07K 14/335: from Lactobacillus (G)
- C07K 14/70567: {Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors}
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 17/00: Drugs for dermatological disorders
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/04: Antibacterial agents
- A61P 35/00: Antineoplastic agents
- C12N 15/70: Vectors or expression systems specially adapted for E. coli
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention provides a novel protein and biologically-active fragments and variants thereof with advantageous therapeutic and cosmetic uses. Also provided are methods of using the proteins, as well as methods of producing the proteins using a recombinant cell. Further provided are recombinant host cells transformed with a polynucleotide sequence that encodes the expression of the proteins.

## Claims

### Claim 1

A protein having one or more therapeutic and/or cosmetic properties, wherein the protein comprises an amino acid sequence selected from:
i) SEQ ID NO: 1;
ii) a variant of SEQ ID NO: 1; and
iii) a fragment of i) or ii)
wherein said variant or fragment is antibacterial, anti-cancer, anti-inflammatory, and/or metabolism modulating; and/or said variant or fragment binds with, or otherwise modulates the activity of, a peroxisome proliferator-activated receptor (PPAR), extracellular signal-regulated kinase (ERK 1/2), and/or glucocorticoid receptor (GR).

### Claim 2 (depends on 1)

The protein of claim 1, comprising SEQ ID NO: 1.

### Claim 3 (depends on 1)

The protein of claim 1, having SEQ ID NO: 1.

### Claim 4 (depends on 1)

The protein of claim 1, wherein the protein binds with, or otherwise modulates the activity of, PPAR is PPARα, PPARβ/δ, and/or PPARγ.

### Claim 5 (depends on 1)

The protein of claim 1, wherein the protein comprises a fragment of at least 70% of SEQ ID NO: 1.

### Claim 6 (depends on 1)

An isolated polynucleotide that encodes a protein of claim 1.

### Claim 7 (depends on 6)

The isolated polynucleotide of claim 6, wherein said isolated polynucleotide encodes SEQ ID NO: 1.

### Claim 8 (depends on 7)

The isolated polynucleotide of claim 7, having SEQ ID NO. 2.

### Claim 9 (depends on 6)

A vector comprising a polynucleotide of claim 6.

### Claim 10 (depends on 9)

The vector of claim 9, comprising a polynucleotide having SEQ ID NO: 2.

### Claim 11 (depends on 1)

A cell comprising an exogenous polynucleotide that encodes a protein of claim 1.

### Claim 12 (depends on 11)

The recombinant cell of claim 11, comprising a polynucleotide that encodes SEQ ID NO: 1.

### Claim 13 (depends on 1)

A method of enhancing the health and/or appearance of a subject's skin, wherein the method comprises administering to the skin a protein of claim 1, or a recombinant cell expressing said protein.

### Claim 14 (depends on 1)

A method for treating inflammation in a subject, wherein said method comprises administering, to a subject in need of such treatment, a therapeutically-effective protein of claim 1, or a recombinant cell expressing said protein.

### Claim 15 (depends on 14)

The method of claim 14, wherein the inflammation is of the respiratory tract or the gastrointestinal tract.

### Claim 16 (depends on 1)

A method for improving maternal and/or fetal health, wherein said method comprises administering, to a subject in need of such improvement, a protein of claim 1, or a cell expressing said protein.

### Claim 17 (depends on 16)

The method of claim 16, used to improve one or more of pre-eclampsia, maternal diabetes, eclampsia, low birth weight, normal pregnancy, intrauterine growth retardation (IUGR), necrotizing enterocolitis and pre-term labor.

### Claim 18 (depends on 1)

A method for treating or preventing an ophthalmologic condition, wherein said method comprises administering, to a subject in need of such treatment or prevention, a therapeutically-effective amount of a protein of claim 1, or a cell expressing said protein.

### Claim 19 (depends on 18)

The method of claim 18, used in the prevention and/or treatment of one or more of diabetic retinopathy; choroidal neovascularization; glaucoma; corneal neovascularization; diabetic macular edema; age-related macular degeneration; diabetic neovascularization; keratitis; corneal limbal stem cell failure; optic neuropathy; dry eye disease; Meibomian gland dysfunction; and allergic conjunctivitis.
